111 related articles for article (PubMed ID: 15025750)
1. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine.
van Riemsdijk MM; Sturkenboom MC; Ditters JM; Tulen JH; Ligthelm RJ; Overbosch D; Stricker BH
Br J Clin Pharmacol; 2004 Apr; 57(4):506-12. PubMed ID: 15025750
[TBL] [Abstract][Full Text] [Related]
2. Neuropsychiatric events during prophylactic use of mefloquine before travelling.
van Riemsdijk MM; Ditters JM; Sturkenboom MC; Tulen JH; Ligthelm RJ; Overbosch D; Stricker BH
Eur J Clin Pharmacol; 2002 Sep; 58(6):441-5. PubMed ID: 12242605
[TBL] [Abstract][Full Text] [Related]
3. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events.
van Riemsdijk MM; Sturkenboom MC; Ditters JM; Ligthelm RJ; Overbosch D; Stricker BH
Clin Pharmacol Ther; 2002 Sep; 72(3):294-301. PubMed ID: 12235450
[TBL] [Abstract][Full Text] [Related]
4. [Malaria chemoprophylaxis: tolerance and compliance with mefloquine and proguanil/chloroquine combination in French tourists].
Carme B; Péguet C; Nevez G
Bull Soc Pathol Exot; 1997; 90(4):273-6. PubMed ID: 9479468
[TBL] [Abstract][Full Text] [Related]
5. [Neuropsychiatric symptoms caused by mefloquine (report of several cases)].
Murai Z; Baran B; Tolna J; Szily E; Gazdag G
Orv Hetil; 2005 Jan; 146(3):133-6. PubMed ID: 15693445
[TBL] [Abstract][Full Text] [Related]
6. [Impact of dynamic change of waist circumference or body mass index in hypertension incidence].
Luo WS; Guo ZR; Hu XS; Zhou ZY; Wu M; Zhang LJ; Liu JC
Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Nov; 45(11):1012-6. PubMed ID: 22336278
[TBL] [Abstract][Full Text] [Related]
7. Mefloquine neurotoxicity: a literature review.
Toovey S
Travel Med Infect Dis; 2009 Jan; 7(1):2-6. PubMed ID: 19174293
[TBL] [Abstract][Full Text] [Related]
8. Neuro-psychiatric effects of antimalarials.
van Riemsdijk MM; van der Klauw MM; van Heest JA; Reedeker FR; Ligthelm RJ; Herings RM; Stricker BH
Eur J Clin Pharmacol; 1997; 52(1):1-6. PubMed ID: 9143859
[TBL] [Abstract][Full Text] [Related]
9. [Neuropsychiatric symptoms in preventive antimalarial treatment with mefloquine: apropos of 2 cases].
Lebain P; Juliard C; Davy JP; Dollfus S
Encephale; 2000; 26(4):67-70. PubMed ID: 11064842
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of mood profiles during malaria chemoprophylaxis: a randomized, double-blind, four-arm study.
Schlagenhauf P; Johnson R; Schwartz E; Nothdurft HD; Steffen R
J Travel Med; 2009; 16(1):42-5. PubMed ID: 19192127
[TBL] [Abstract][Full Text] [Related]
11. [Mefloquine: neuropsychiatric adverse effects are often severe and persistent long after withdrawal of the drug].
Jensen JJ
Ugeskr Laeger; 1998 Apr; 160(16):2413. PubMed ID: 9616091
[No Abstract] [Full Text] [Related]
12. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.
Aarnoudse AL; van Schaik RH; Dieleman J; Molokhia M; van Riemsdijk MM; Ligthelm RJ; Overbosch D; van der Heiden IP; Stricker BH
Clin Pharmacol Ther; 2006 Oct; 80(4):367-74. PubMed ID: 17015054
[TBL] [Abstract][Full Text] [Related]
13. [Adverse effects associated with antimalarial chemoprophylaxis].
Corominas N; Gascón J; Mejías T; Caparrós F; Quintó L; Codina C; Ribas J; Corachán M
Med Clin (Barc); 1997 May; 108(20):772-5. PubMed ID: 9265081
[TBL] [Abstract][Full Text] [Related]
14. Eye disorders reported with the use of mefloquine (Lariam(®)) chemoprophylaxis--A drug safety database analysis.
Adamcova M; Schaerer MT; Bercaru I; Cockburn I; Rhein HG; Schlagenhauf P
Travel Med Infect Dis; 2015; 13(5):400-8. PubMed ID: 26119539
[TBL] [Abstract][Full Text] [Related]
15. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study.
Overbosch D; Schilthuis H; Bienzle U; Behrens RH; Kain KC; Clarke PD; Toovey S; Knobloch J; Nothdurft HD; Shaw D; Roskell NS; Chulay JD;
Clin Infect Dis; 2001 Oct; 33(7):1015-21. PubMed ID: 11528574
[TBL] [Abstract][Full Text] [Related]
16. [Clinical experiences with mefloquine in tropical malaria--a prospective study].
Held T; Trautmann M; Weinke T; Mravak S
Immun Infekt; 1991 Jun; 19(3):83-6. PubMed ID: 1916870
[TBL] [Abstract][Full Text] [Related]
17. Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands.
van Riemsdijk MM; Sturkenboom MC; Pepplinkhuizen L; Stricker BH
J Clin Psychiatry; 2005 Feb; 66(2):199-204. PubMed ID: 15705005
[TBL] [Abstract][Full Text] [Related]
18. [Neuropsychiatric side effects of malarial prophylaxis with mefloquine (Lariam)].
Minei-Rachmilewitz T
Harefuah; 1999 Jul; 137(1-2):25-7, 87. PubMed ID: 10959270
[TBL] [Abstract][Full Text] [Related]
19. Mefloquine-induced pneumonitis.
Soentjens P; Delanote M; Van Gompel A
J Travel Med; 2006; 13(3):172-4. PubMed ID: 16706949
[TBL] [Abstract][Full Text] [Related]
20. Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective study.
Rønn AM; Rønne-Rasmussen J; Gøtzsche PC; Bygbjerg IC
Trop Med Int Health; 1998 Feb; 3(2):83-8. PubMed ID: 9537268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
